Disclosure Policy

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to The Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

PRESENTING FACULTY

The following presenting faculty reported the following relevant financial relationship(s) that they or their spouse/partner have with commercial interests:

Anders Carlson, MD has had his institution receive remuneration for consulting and/or clinical research from Novo Nordisk, Sanofi, Medtronic, Dexcom, Abbott, Eli Lilly, and Insulet. 

Adi Cohen, MD has received research support from Eli Lilly and Amgen. 

Maria Fleseriu, MD has received scientific consulting fees from Novarits and Strongbridge; and has had her institution receive research support from Novartis, Millendo, and Strongbridge

George J. Kahaly, MD, PhD has served as a consultant to Quidel USA; and has had his institution receive a research grant from Quidel. 

E. Micheal Lewiecki, MD has had his employer receive research grants from Radius, Amgen, Mereo, and Bindex; has received income for service on scientific advisory board or consulting from AMgen, Radius, Alexion, Sandoz, Samsung, and Bioepis; has served on speakers bureaus for Radius, Alexion; has worked on project development for University of New Mexico; has received royalties from UpToDate sections; and has served as a board member for the National Osteoporosis Foundation, International Society for Clinical Densitometry, and Osteoporosis Foundation of New Mexico. 

Mark E. Molitch, MD has served as a consultant to Merck, Pfizer, Novartis, Chiasma, Corcept and Janssen; and has worked as a primary investigator for Janssen, Novartis, and Bayer. 

David M. Nathan, MD has received research support from Alere, Inc (now Abbott). 

Mary-Elizabeth Patti, MD has served as a collaborator for NIH R44 grant funded by Xeris Pharmaceuticals; has worked as a consultant for Fractyl and Eiger Pharmaceuticals; and has received investigator-initiated research support to her institution from Xeris Pharmaceuticals and Dexcom.

Micol Rothman, MD has served on the Professional Practice Committee of the American Society for Bone and Mineral Research.

Donna H. Ryan, MD has received consulting fees from Amgen, Bausch Health, Boeringer Ingelheim, Gila Therapeutics, IFA Celtic, Janssen, KVK Tech, Novo Nordisk, Phenomix, Quintiles, Real Appeal (United Health), ReDesign Health, Sanofi, and Scientific Intake; has served on the speakers bureau for Novo Nordisk; has an ownership interest in Gila Therapeutics, Phenomix, Xeno Bioscience, Epitomee, ReDesign Health and Scientific Intake; and has served on the SELECT Steering Committee for Novo Nordisk. 

Joseph G. Verbalis, MD has received consulting fees from Ferring Pharmaceuticals; and has received research support from Corcept Therapeutics. 

Nelson B. Watts, MD has served as a consultant for Abbvie, Amgen, and Sanofi; and served as a speaker for Amgen and Radius. 

Carol Wysham, MD has served as a consultant to Astra Zeneca, Abbott, Janssen, Novo Nordisk, and Sanaofi; has been in the speakers bureau for Astra Zeneca, Boehringer Ingelheim, Janssen, Novo Nordisk, and Sanofi; and has received research funding from Abbott, Novo Nordisk and Mylan. 

The following faculty report no relevant financial relationships: Shehzad S. Basaria, MD; Anuja Dokras, MD, PhD; Stephanie Fish, MD; Scott Kahan, MD, MPH; Carol J. Levy, MD, CDE; Shlomo Melmed, MD; Lynnette K. Nieman, MD;  Elizabeth N. Pearce, MD, MSc; Matthew D. Ringel, MD; Robert C. Stanton, MD; Lisa R. Tannock, MD; Anand Vaidya, MD, MMSc; Margaret E. Wierman, MD; William F. Young, Jr, MD, MSc.

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

DISCLAIMERS

The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of the Endocrine Society.

USE OF PROFESSIONAL JUDGMENT:

The educational content in this self-assessment test relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.

DRUGS AND DOSAGES:

When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.

PRIVACY AND CONFIDENTIALITY STATEMENT

The Endocrine Society will record learner’s personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.

ACKNOWLEDGMENT OF COMMERCIAL SUPPORT

The Endocrine Society is proud to partner with industry to advance excellence and promote scientific discovery, medical practice and human health. These sessions were supported by: